BP PLC
16 December 2005
BP SALE OF INNOVENE TO INEOS COMPLETED
BP announced today that the sale of Innovene, its petrochemicals group, to INEOS
completed at 13.30 hours, UK time.
'The sale of Innovene has been the biggest single divestment in BP's history and
with hard work on both sides we have completed it in just 10 weeks - ahead of
schedule and still in 2005. This is excellent news for BP's shareholders and I
wish Ineos and its staff success for the future,' said Lord Browne, BP group
chief executive.
Notes to editors:
• BP announced on 7th October 2005 that it would sell Innovene, its olefins,
derivatives and refining group, to UK-based INEOS. The $9 billion cash sale
included Innovene's manufacturing sites, markets and technologies.
• The European Commission cleared the proposed acquisition under the EU Merger
Regulation on 9th December.
• BP first announced the intention of separating its olefins and derivatives
business from its petrochemicals portfolio in April 2004 with an initial
public offering (IPO) as one, possible, disposal option. In the interim, it
received a number of approaches from companies considering a trade sale.
Further media enquiries:
BP: Press Office +44 (0)207 496 4076
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.